CagriSema
19 articles on CagriSema, written by Shotlee and medically reviewed for clinical accuracy.
CagriSema Breakthrough: New Dual Therapy Delivers Major Weight Loss in Diabetes Trials
Explore the groundbreaking REIMAGINE trial results for CagriSema, a novel dual-agonist therapy showing superior glycemic control and weight loss in type 2 diabetes patients.
7 min read
Retatrutide's Triumph: Lilly's Triple Agonist Redefines Weight Loss Potential
Eli Lilly's retatrutide is making waves in the weight loss landscape. This comprehensive look delves into its Phase III results, comparing it to existing treatments and exploring its potential impact on obesity management.
6 min read
Novo's Woes Despite Ozempic's Explosive Growth
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
5 min read
Novo Nordisk Stock Erases Wegovy Gains After CagriSema Miss
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
5 min read
Ireland Set to Ride Weight-Loss Drug Revolution with Eli Lilly
Just as smartphones propelled Ireland's economy post-financial crisis, GLP-1 weight-loss drugs like Eli Lilly's Mounjaro and Zepbound are set to do the same. With factories in Kinsale and Limerick producing key ingredients, Ireland eyes massive tax windfalls and export spikes. Gallup data shows US obesity falling to 37%, crediting these therapies.
5 min read
Novo Nordisk Investigated Over CagriSema Trial Results - NVO
Novo Nordisk faces an investor investigation by DJS Law Group over claims of misleading statements about its CagriSema weight loss drug trial. The phase 3 study failed to demonstrate non-inferiority against Eli Lilly's tirzepatide after 84 weeks, triggering a sharp 15%+ premarket stock plunge on February 23, 2026. Investors affected by the drop may have rights under securities laws.
5 min read
Viking Therapeutics Shares Surge 12% as Novo's CagriSema Stumbles
Shares of Viking Therapeutics surged approximately 12% on Monday following a clinical setback for Novo Nordisk's next-generation obesity drug CagriSema, which underperformed Eli Lilly's Tirzepatide in a pivotal Phase 3 trial. This shift highlights intensifying competition in the GLP-1 obesity market. Investors are eyeing Viking's VK2735 as a promising contender.
5 min read
CagriSema Falls Short vs. Tirzepatide in Obesity Drug Trial
In a pivotal head-to-head trial, Novo Nordisk's next-generation obesity drug CagriSema delivered 23% body weight reduction over 84 weeks, missing the mark against Eli Lilly's tirzepatide at 25.5%. This setback highlights the intense competition in the weight-loss market. Novo shares dropped 11%, while Lilly's rose 4%.
5 min read
New GLP-1 Weight-Loss Drugs Stronger Than Wegovy and Zepbound
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
8 min read
CagriSema Superior to Semaglutide for HbA1c, Weight Loss in T2D
New topline data from the REIMAGINE 2 trial reveal CagriSema outperforms semaglutide in HbA1c reduction and weight loss for adults with type 2 diabetes inadequately controlled on metformin. Patients on CagriSema 2.4mg/2.4mg saw a 1.91% point HbA1c drop and 14.2% body weight loss at 68 weeks. This combination of cagrilintide and semaglutide sets a new benchmark in T2D therapy.
6 min read
Oral Wegovy: Benefits, Dosing, and What Patients Need to Know
Novo Nordisk's oral Wegovy has launched with impressive prescription volumes, offering a pill alternative to injections for weight management. Learn about its efficacy, ideal candidates, dosing, and how it fits into GLP-1 therapy. This guide breaks down the science and practical advice for patients.
5 min read
Oral Wegovy Pill: Novo Nordisk's Game-Changer for Obesity
Novo Nordisk's launch of an oral Wegovy pill marks a pivotal shift in GLP-1 therapy, offering a convenient alternative to injections for obesity treatment. This guide explores its mechanism, efficacy, safety profile, and how it stacks up against rivals like Eli Lilly's orforglipron. Learn what this means for your weight loss journey.
4 min read
Novo Nordisk vs Eli Lilly: GLP-1 Drugs Showdown
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
5 min read
Novo Nordisk GLP-1s: Ozempic, Wegovy, Rybelsus Guide
Novo Nordisk has redefined obesity and diabetes care with its GLP-1 powerhouse: semaglutide brands Ozempic, Wegovy, and Rybelsus. These injectables and oral options deliver substantial weight loss, glycemic control, and cardiovascular protection. Discover how they work, compare to competitors, and optimize your treatment.
4 min read
GLP-1 Receptor Agonists and Next-Generation Metabolic Hormone Therapies for Chronic Kidney Disease
Clinical trials across the cardiovascular-kidney-metabolic spectrum demonstrate kidney protective effects of incretin-based therapies. Multiple studies show GLP-1RAs and dual GIP/GLP-1RAs reduce kidney disease progression, albuminuria, and kidney failure risk in patients with type 2 diabetes and chronic kidney disease.
10 min read
GLP-1s: Understanding the Evolution of Weight-Loss Medications
Weight-loss drugs, particularly those mimicking GLP-1, have gained significant traction. This article delves into their functionality, efficacy, side effects, accessibility challenges, and the emergence of more accessible pill versions.
6 min read
The Next Generation of Ozempic: Exploring the Future of Weight Loss
Blockbuster weight-loss shots are evolving, with new treatments in development that aim to improve upon current injections. Drugmakers are developing a new wave of GLP-1 treatments, with several promising candidates in the pipeline. These experimental treatments aim to address some of the biggest gripes about today's injections.
4 min read
Ozempic 2.0 is Coming: A Potentially More Transformative Treatment
A new generation of weight loss medications is emerging, promising to be even more effective for human health. These include pills, more powerful injectables, and novel compounds that may have reduced side effects or require only monthly administration.
7 min read
Another Round of Weight-Loss Medications is on the Horizon
The demand for weight-loss drugs is surging. New medications promise increased effectiveness and easier administration, including oral options. Several pharmaceutical companies are developing improved injectable drugs.
4 min read